Our pipeline includes differentiated antibody programs poised to bring a new generation of therapies to patients.
Triveni Bio
Pipeline
A pipeline with the power to redefine standard of care
TRIV-509
A potential first-in-class, dual specific, half-life extended monoclonal antibody that inhibits active kallikreins 5 and 7 (KLK5/7)
TRIV-509 is currently in a Phase 2a proof-of-concept clinical trial for the treatment of moderate-to-severe atopic dermatitis. TRIV-509 has successfully completed Phase 1a healthy volunteer and Phase 1b proof-of-mechanism trial with no potential safety risks identified. Designed to address inflammation, itch and barrier disruption, TRIV-509 has the potential to expand into other disorders such as Netherton syndrome, other epidermal differentiation disorders (EDDs), and more.
Program information:
Phase 1a Healthy volunteer Study Completed
Phase 1b AD Mechanistic barrier Study Completed
Phase 2a AD Proof of Concept Study
“We are thrilled to advance our portfolio of novel KLK5/7 programs, TRIV-509 and TRIV-573, across patient studies as we aim to transform the treatment paradigm of atopic dermatitis by directly targeting key enzymes implicated in the vicious cycle of tissue damage.”
Bhaskar Srivastava, MD PhD, Chief Medical Officer, Triveni Bio
TRIV-573
A second-generation, half-life extended bispecific antibody combining dual inhibition of KLK5/7 with a validated anti-IL-13 mechanism
TRIV-573 is currently in two clinical studies including a Phase 1 study to assess safety and tolerability and a Phase 2 proof-of-concept trial in moderate-severe atopic dermatitis.
With its combination of orthogonal validated mechanisms, TRIV-573 is being developed as a potential treatment for a range of I&I disorders including asthma, eosinophilic esophagitis (EoE), and more.
Program information:
Phase 1a Healthy volunteer Study
Phase 2 AD Proof of Concept Study“Atopic dermatitis remains a significant burden for many patients. By addressing skin barrier dysfunction through KLK5/7 inhibition, Triveni is advancing a new therapeutic strategy rooted in the biology of disease with potential to make meaningful change in patients’ lives.”
Christopher Bunick, MD PhD, Associate Professor of Dermatology, Program in Translational Biomedicine, Yale School of Medicine
TRIV-920
A first-in-class monoclonal antibody with potent dual inhibition of active trypsin 1 and 2
TRIV-920 is in preclinical development for the treatment of pancreatitis, a condition with high unmet need and no approved therapies. In preclinical models of hereditary pancreatitis (hPRSS1R122H), TRIV-920 has demonstrated significant reduction in key markers of both acute and chronic pancreatic damage, highlighting its potential as a first-in-class treatment option.
Meet the team behind the science